SGMOQ — Sangamo Therapeutics Share News
0.000.00%
Last trade - 00:00- $18.64m
- -$8.94m
- $39.55m
Sangamo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Sangamo Therapeutics Q1 EPS USD -0.14 Vs. IBES Estimate USD -0.13
Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System
Sangamo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Sangamo Therapeutics Q4 EPS USD -0.11 Vs. IBES Estimate USD -0.09
Sangamo Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Sangamo Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Comm services, Nvidia, US insurers
U.S. STOCKS ON THE MOVE-Boeing, US banks, Flagstar Financial
Sangamo Therapeutics plunges after Pfizer terminates partnership
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal (updated)
Sangamo Therapeutics plunges after Pfizer terminates partnership
Sangamo to reclaim hemophilia A therapy rights post Pfizer termination
Brief: Sangamo Therapeutics To Regain Full Rights To Hemophilia A Gene Therapy Program Following Pfizer’S Decision To Cease Development Of Giroctocogene Fitelparvovec
Brief: Sangamo Therapeutics & Astellas Enter Capsid License Agreement
Sangamo Therapeutics rises after FDA clears application to start trial for pain treatment
Brief: Sangamo Therapeutics Announces U.S. FDA Clearance Of IND Application For ST-503